Literature DB >> 11309268

Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice.

M Hiramatsu1, K Inoue, A Ambo, Y Sasaki, T Kameyama.   

Abstract

Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2) (SK-9709) is a dynorphin derivative in which the peptide bond was replaced with a psi (CH(2)NH) bond. In the present study, the antinociceptive effects of SK-9709 were determined in an acetic acid-induced writhing test and a hot-plate test. In the acetic acid-induced writhing test, significant antinociceptive effects were observed after subcutaneous (s.c.), intracerebroventricular (i.c.v.) and intrathecal (i.t.) injection of SK-9709, with maximal effects at 120, 30 and 15 min, respectively. The antinociceptive effects were dose-dependent and ED(50) values (range of 95% confidence limits) after s.c., i.c.v. and i.t. injection were 1.36 (0.61 - 3.02) micromol kg(-1), 2.11 (1.18 - 3.79) and 0.79 (0.61 - 1.03) nmol per mouse, respectively. The effects of SK-9709 (s.c., i.c.v. and i.t.) were reversed by the opioid receptor antagonist naloxone (1.36 micromol kg(-1), s.c.). The effects of SK-9709 (s.c.) were also reversed by the selective mu-opioid receptor antagonist beta-funaltrexamine (4.7 nmol per mouse, i.c.v.), and kappa-opioid receptor antagonist nor-binaltorphimine (4.9 nmol per mouse, i.t.). In the hot-plate test, the antinociceptive effect of SK-9709 (s.c., i.c.v. and i.t.) was also dose-dependent with the maximal peak effect at 120, 15 and 15 min similarly to the acetic acid-induced writhing test. The antinociceptive effects were dose-dependent and ED(50) values (range of 95% confidence limits) after s.c., i.c.v. and i.t. injection were 39.1 (5.4 - 283.0) micromol kg(-1), 6.5 (4.0 - 10.7) and 7.4 (5.0 - 11.0) nmol per mouse, respectively. These findings indicated that systemically administered SK-9709 produced long-lasting antinociceptive effects and these effects were mediated by both supra-spinal mu- and spinal kappa-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309268      PMCID: PMC1572722          DOI: 10.1038/sj.bjp.0703982

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

2.  No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia.

Authors:  C Stein; M Pflüger; A Yassouridis; J Hoelzl; K Lehrberger; C Welte; A H Hassan
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Dynorphin and dynorphin are ligands for the kappa-subtype of opiate receptor.

Authors:  A D Corbett; S J Paterson; A T McKnight; J Magnan; H W Kosterlitz
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

4.  Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo.

Authors:  J Z Chou; B T Chait; R Wang; M J Kreek
Journal:  Peptides       Date:  1996       Impact factor: 3.750

5.  Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.

Authors:  Q Jiang; A Seyed-Mozaffari; A Sebastian; S Archer; J M Bidlack
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

6.  Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone.

Authors:  T W Vanderah; T Laughlin; J M Lashbrook; M L Nichols; G L Wilcox; M H Ossipov; T P Malan; F Porreca
Journal:  Pain       Date:  1996-12       Impact factor: 6.961

7.  Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action.

Authors:  A I Faden; T P Jacobs
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

8.  Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism.

Authors:  A I Faden
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

9.  [D-Pro10]-dynorphin(1-11) is a kappa-selective opioid analgesic in mice.

Authors:  J E Gairin; R Gout; J C Meunier; J Cros
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

10.  Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues.

Authors:  H Yoshino; T Nakazawa; Y Arakawa; T Kaneko; Y Tsuchiya; M Matsunaga; S Araki; M Ikeda; K Yamatsu; S Tachibana
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

View more
  8 in total

Review 1.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

2.  Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn.

Authors:  A N Carey; K Borozny; J V Aldrich; J P McLaughlin
Journal:  Eur J Pharmacol       Date:  2007-05-13       Impact factor: 4.432

Review 3.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

4.  Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats.

Authors:  Suliman I Al-Fayoumi; Boglarka Brugos; Vikram Arya; Esther Mulder; Barbel Eppler; Andre P Mauderli; Günther Hochhaus
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

5.  Opioid Peptides: Potential for Drug Development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  Drug Discov Today Technol       Date:  2012

Review 6.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

7.  Biotransformation of beta-endorphin and possible therapeutic implications.

Authors:  Naghmeh H Asvadi; Michael Morgan; Amitha K Hewavitharana; P Nicholas Shaw; Peter J Cabot
Journal:  Front Pharmacol       Date:  2014-02-19       Impact factor: 5.810

Review 8.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.